Research
Hormonal
GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists provide clinically meaningful weight loss of approximately 15%–21% at 68–72 weeks in major trials.
Practitioners can expect significant weight loss in patients using GLP-1 therapies over the specified duration.
StrongSupportsmedium confidence
GLP-1-based therapies provide clinically meaningful weight loss (approximately 15%–21% at 68–72 weeks in major trials).
Why this rating
Based on major trials mentioned in the abstract.
Source
Reframing obesity as a chronic, multifactorial disease: Clinical implications of GLP-1–based therapies
Roopesh Jain · Advances in Biomedical and Health Sciences · 2026
review · n=17604
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →